Track topics on Twitter Track topics that are important to you
AbbVie is to receive $330 million after Reata Pharmaceuticals reacquired development, manufacturing and commercialisation rights to a portfolio of Nrf2 activators, including bardoxolone and omaveloxolone.
More specifically, Reata stated it has regained rights to bardoxolone outside the US in addition to global rights to omaveloxolone and other Nrf2 activators.
Original Article: AbbVie set to receive $330m after exiting Reata dealNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...